Aktienanalyse zu MediciNova Inc (MNOV)MNOVMediciNova Inc

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MediciNova Inc is a good buy right now due to its current price of $1.44, which is significantly below the analyst price target of $6, indicating substantial upside potential. Additionally, the company has shown a remarkable gross margin of 69.31% in Q2 2026, suggesting strong profitability potential as it continues to develop its drug candidates. However, the main risk is the negative earnings per share (EPS) estimate of -0.06 for the upcoming earnings report on November 11, 2026, which could impact investor sentiment if not met.

1 analysts cover MNOV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.